Exact Mass: 383.00515240000004
Exact Mass Matches: 383.00515240000004
Found 77 metabolites which its exact mass value is equals to given mass value 383.00515240000004,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Ceftizoxime
C13H13N5O5S2 (383.03580880000004)
A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders. [PubChem] J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DD - Third-generation cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
clofarabind-5'-monophosphate
clofarabind-5-monophosphate is a metabolite of clofarabine. Clofarabine is a purine nucleoside antimetabolite marketed in the U.S. and Canada as Clolar. In Europe and Australia/New Zealand the product is marketed under the name Evoltra. It is FDA-approved for treating relapsed or refractory acute lymphoblastic leukaemia (ALL) in children after at least two other types of treatment have failed. It is not known if it extends life expectancy. (Wikipedia)
Althiazide
C11H14ClN3O4S3 (382.98349540000004)
C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic
N-(3,5-Bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide
3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile
C17H12F3NO4S (383.04391080000005)
Belzutifan
C17H12F3NO4S (383.04391080000005)
C(=O)(O)CS(=O)C1=C(N2C(C(C2C1)C(C)OS(=O)(=O)O)=O)C(=O)O
althiazide
C11H14ClN3O4S3 (382.98349540000004)
C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic
6-(2,6-Dichlorophenyl)-8-methyl-2-methylsulfonyl-8H-pyrido[2,3-d]pyrimidin-7-one
C15H11Cl2N3O3S (382.98981560000004)
(2,3-Dihydro-2-thioxo-3-benzoxazolyl)phosphonic acid diphenyl ester
C19H14NO4PS (383.0381134000001)
4-(4-BROMOPHENYL)-2-(4-(TRIFLUOROMETHYL)PHENYL)THIAZOLE
C16H9BrF3NS (382.95911300000006)
potassium [[N,N-ethylenebis[N-(carboxymethyl)glycinato]](4-)-N,N,O,O,ON,ON]ferrate(1-)
3-BENZYLOXY-4-IODO-5-NITRO-BENZALDEHYDE
C14H10INO4 (382.9654570000001)
Echothiophate Iodide
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010277 - Parasympathomimetics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D008916 - Miotics C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor D004791 - Enzyme Inhibitors
2-([(4-bromophenyl)sulfonyl]amino)-3-phenylpropanoic acid
C15H14BrNO4S (382.9826864000001)
5-Chloro-3-ethyl-2-methylbenzothiazolium p-toluenesulfonate
(2-amino-4,5-dihydroxy-1-oxo-6-sulfooxyhexan-3-yl) hydrogen sulfate,sodium
4-(4-Bromo-1H-pyrazol-1-yl)-N-cyclohexylbenzenesulfonamide
1-acetamido-8-hydroxy-3,6-naphthalenedisulfonic acid monosodium salt
6-Bromo-13-Thia-2,4,8,12,19-Pentaazatricyclo[12.3.1.1~3,7~]nonadeca-1(18),3(19),4,6,14,16-Hexaene 13,13-Dioxide
C13H14BrN5O2S (383.00515240000004)
Belzutifan
C17H12F3NO4S (383.04391080000005)
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents D000970 - Antineoplastic Agents Belzutifan (PT2977) is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. Belzutifan, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. Belzutifan is a potential treatment for clear cell renal cell carcinoma (ccRCC)[1].
2,5-dichloro-N-(1,5,6-trimethyl-4-benzimidazolyl)benzenesulfonamide
1-Bromo-8,8-dimethyl-8,9-dihydro-5-morpholino-6h-isothiazolo[5,4-b]pyrano[4,3-d]pyridine
N-[3,4-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-chlorobenzamide
2-Bromo-8-hydroxyspiro[6,10,15-triazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),2(7),4,8,10,12(16)-hexaene-3,4-cyclohex-2-ene]-1-one
3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile
C17H12F3NO4S (383.04391080000005)
[(1R)-1-[(7S)-2-amino-7-methyl-4-oxo-7,8-dihydro-3H-pteridin-6-yl]ethyl] phosphono hydrogen phosphate
4,9,14-triamino-1,2,11,12-tetraoxa-6,7-dithiacycloheptadecane-3,10,13,17-tetrone
6-[[(4-Chlorophenyl)thio]methyl]-2-phenyl-1,7-dihydropyrazolo[3,4-b]pyridine-3,4-dione
C19H14ClN3O2S (383.04952140000006)
5-bromo-N-[2-(3-pyridinyl)-1,3-benzoxazol-5-yl]-2-furancarboxamide
3,7-dichloro-N-[3-(1-imidazolyl)propyl]-6-methoxy-1-benzothiophene-2-carboxamide
3-(2-chlorophenyl)-N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-5-methyl-4-isoxazolecarboxamide
C19H14ClN3O2S (383.04952140000006)
N-[3-(1,3-benzothiazol-2-yl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl]-2,2,2-trifluoroacetamide
5-Bromo-2-furancarboxylic acid [2-[1-(2-methoxyethyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl] ester
2-(4-chlorophenoxy)-N-(2-thiophen-2-yl-3-imidazo[1,2-a]pyridinyl)acetamide
C19H14ClN3O2S (383.04952140000006)
5-Bromo-4-chloro-2-(4-methoxybenzamido)benzoic acid
C15H11BrClNO4 (382.95599360000006)
2-(2-chloro-4-fluorophenoxy)-N-[5-(3,4-difluorophenyl)-1,3,4-oxadiazol-2-yl]acetamide
(2S)-2-chloro-3-{2-chloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl}propanoic acid
C13H10Cl2F3N3O3 (383.00512860000003)
(2R)-2-chloro-3-{2-chloro-5-[4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-4-fluorophenyl}propanoic acid
C13H10Cl2F3N3O3 (383.00512860000003)
sodium (2R)-2-(4-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxy}phenoxy)propanoate
C15H10ClF3NNaO4 (383.0148126000001)
sodium (2S)-2-(4-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxy}phenoxy)propanoate
C15H10ClF3NNaO4 (383.0148126000001)
ceftizoxime
C13H13N5O5S2 (383.03580880000004)
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DD - Third-generation cephalosporins A parenteral third-generation cephalosporin, bearing a 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino group at the 7beta-position. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
Nelonemdaz
Nelonemdaz (Salfaprodil free base) is an NR2B-selective and uncompetitive antagonist of N-methyl-D-aspartate (NMDA). Nelonemdaz is also a free radical scavenger. Nelonemdaz has excellent neuroprotection against NMDA- and free radical-induced cell death[1][2].
PT-2385
C17H12F3NO4S (383.04391080000005)
PT-2385 is a selective HIF-2α inhibitor with a Ki of less than 50 nM[1][2].
(1r)-3-bromo-6',10',15'-triazaspiro[cyclohexane-1,3'-tetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadecane]-1'(15'),2,2'(7'),4',9'(16'),11'-hexaene-4,8'-dione
(2r)-4-(4-bromo-2,6-dichlorophenoxy)-2-(trimethylammonio)butanoate
C13H16BrCl2NO3 (382.96905460000005)